AmpliPhi BioSciences is a biotechnology company engaged in developing and commercializing novel bacteriophage-based therapeutics for human and animal applications. AmpliPhi’s product development programs target Gram-negative infections that are often resistant to existing antibiotic treatments. The company was created through the 2011 merger of BioControl Ltd. and Targeted Genetics, Inc. and the subsequent combination with Special Phage Services in 2012. For more information, visit the company’s Web site at www.ampliphibio.com.